Hbl-2 In Vivo Anti-Tumor Efficacy Assay

This assay is to provide Hbl-2-based In Vivo Anti-Tumor Efficacy Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

Hbl-2

Human

The HBL-2 cell line is derived from an AIDS-SNCCL (AIDS-associated small non-cleaved cell lymphoma) patient. After immunophenotypic and molecular genetic analysis, the HBL-2 was established from the original tumor clones. The HBL-2 cell line presents surface immunoglobulin and B-cell restricted markers as well as a phenotype consistent with SNCCL; the cell line also displays clonal immunoglobulin gene rearrangement. The HBL-2 cell line is considered useful as a biological model to study AIDS-associated non-Hodgkin lymphomagenesis (AIDS-NHL) and the impacts of biological, immunological, and viral factors involved.

Mantle Cell Lymphoma; MCL

Oncology

In Vivo Anti-Tumor Efficacy Assay

After positive anti-tumor efficacy data is concluded using in vitro assays, we can start to initiate in vivo anti-tumor efficacy studies. Creative Biolabs offers a wide variety of PDX or CDX models to facilitate the efficacy studies. This assy will be used to evaluate the anti-tumor efficacy of your therapeutic candidates, such as small molecules, antibodies, CARTs or other biologics. Detailed group set up and other plans will be discussed according to your specific requirements.

Oncology In Vivo Assays